Browsing: novo nordisk

Novo Nordisk launches Wegovy in China, targeting the country’s 180 million people with obesity. Priced at ¥1,400 ($192 USD) per starter dose, it faces accessibility challenges as it’s not covered by national insurance. The move heightens competition with Eli Lilly.

Uncover how Novo Nordisk’s Wegovy stands apart from its sibling drug Ozempic, from primary usage to public perception.

Novo Nordisk is making headway in transforming the Ozempic injection into an oral pill, with promising early results.